Clinical Trial Update: Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 Lung-MAP trial evaluating the PARP inhibitor rucaparib in stage IV or recurrent non-small cell lung cancer patients with LOH-high tumors and/or deleteri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• RUBRACA (RUCAPARIB)

Snippet

Sponsor: SWOG Cancer Research Network | Conditions: Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation | Phase 2 | Status: COMPLETED | Results posted: 2022-10-19